{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:55:23Z","timestamp":1790625323797,"version":"4.1.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Direct oral anticoagulant (DOACs) use for pediatric venous thromboembolism has increased, yet data on reversal strategies using 4-factor prothrombin complex concentrate (4F-PCC) remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Observation:<\/jats:title>\n                    <jats:p>We report the first case of intracranial hemorrhage (ICH) in a patient receiving rivaroxaban who underwent reversal with 4F-PCC. An 11-year-old male with sinusitis complicated by multifocal intracranial abscesses, and superior sagittal sinus thrombus treated with rivaroxaban, was found to have ICH. For urgent craniotomy, rivaroxaban was reversed with 2223 units (\u223c45 units\/kg) 4F-PCC. No thromboembolism occurred within 3 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This case adds to the limited literature supporting 4F-PCC for DOAC reversal in pediatrics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mph.0000000000003261","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:00:36Z","timestamp":1787155236000},"page":"353-357","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Emergent Reversal of Intracranial Hemorrhage Using 4-Factor Prothrombin Complex Concentrate in a Pediatric Patient"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4377-9221","authenticated-orcid":false,"given":"Ruchi P.","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri","family":"Bicking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Clouser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"issue":"suppl 1","key":"R4-20260928","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1097\/PCC.0000000000000623","article-title":"Pediatric cardiac intensive care society 2014 consensus statement: pharmacotherapies in cardiac critical care anticoagulation and thrombolysis","volume":"17","author":"Giglia","year":"2016","journal-title":"Pediatr Crit Care Med"},{"key":"R5-20260928","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood.2022018966","article-title":"How I treat pediatric venous thromboembolism in the DOAC era","volume":"143","author":"Bhat","year":"2024","journal-title":"Blood"},{"key":"R6-20260928","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","article-title":"Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"R7-20260928","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1182\/bloodadvances.2024015328","article-title":"American Society of Hematology\/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients","volume":"9","author":"Monagle","year":"2025","journal-title":"Blood Adv"},{"key":"R10-20260928","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1182\/bloodadvances.2018024786","article-title":"American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism","volume":"2","author":"Monagle","year":"2018","journal-title":"Blood Adv"},{"key":"R11-20260928","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","article-title":"Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","volume":"7","author":"Male","year":"2020","journal-title":"Lancet Haematol"},{"key":"R12-20260928","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/S2352-3026(20)30368-9","article-title":"Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b\/3, non-inferiority trial","volume":"8","author":"Halton","year":"2021","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"R13-20260928","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/blood-2024-198612","article-title":"Efficacy and safety of apixaban for pediatric patients requiring anticoagulation for treatment of venous thromboembolism","volume":"144","author":"Driscoll","year":"2024","journal-title":"Blood"},{"key":"R14-20260928","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1160\/TH15-12-0964","article-title":"Age dependency for coagulation parameters in paediatric populations. Results of a multicentre study aimed at defining the age-specific reference ranges","volume":"116","author":"Toulon","year":"2016","journal-title":"Thromb Haemost"},{"key":"R15-20260928","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1111\/j.1538-7836.2012.04905.x","article-title":"Age dependency of coagulation parameters during childhood and puberty","volume":"10","author":"Appel","year":"2012","journal-title":"J Thromb Haemost"},{"key":"R16-20260928","doi-asserted-by":"crossref","first-page":"e500","DOI":"10.1016\/S2352-3026(19)30161-9","article-title":"Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies","volume":"6","author":"Monagle","year":"2019","journal-title":"Lancet Haematol"},{"key":"R17-20260928","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12028-015-0222-x","article-title":"Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine","volume":"24","author":"Frontera","year":"2016","journal-title":"Neurocrit Care"},{"key":"R18-20260928","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"ANNEXA-4 investigators. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"R19-20260928","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Tomaselli","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R20-20260928","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.25475","article-title":"Reversal of direct oral anticoagulants: guidance from the Anticoagulation Forum","volume":"94","author":"Cuker","year":"2019","journal-title":"Am J Hematol"},{"key":"R21-20260928","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N Engl J Med"},{"key":"R22-20260928","doi-asserted-by":"crossref","first-page":"18","DOI":"10.14740\/cr1342","article-title":"Prothrombin complex concentrates to treat coagulation disturbances: an overview with a focus on use in infants and children","volume":"13","author":"Munlemvo","year":"2022","journal-title":"Cardiol Res"},{"key":"R23-20260928","doi-asserted-by":"crossref","first-page":"1182.e1","DOI":"10.1016\/j.ajem.2015.10.041","article-title":"Emergent pediatric anticoagulation reversal using a 4-factor prothrombin complex concentrate","volume":"34","author":"Adams","year":"2016","journal-title":"Am J Emerg Med"},{"key":"R24-20260928","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1055\/s-0039-1700953","article-title":"Single-center use of prothrombin complex concentrate in pediatric patients","volume":"9","author":"Karube","year":"2020","journal-title":"J Pediatr Intensive Care"},{"key":"R25-20260928","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/1060028015613362","article-title":"Use of 4-factor prothrombin concentrate (Kcentra) in hospitalized pediatric patients","volume":"50","author":"Beaty","year":"2016","journal-title":"Ann Pharmacother"},{"key":"R26-20260928","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/vox.12353","article-title":"Four-factor prothrombin complex concentrates in paediatric patients: a retrospective case series","volume":"110","author":"Noga","year":"2016","journal-title":"Vox Sang"},{"key":"R27-20260928","doi-asserted-by":"crossref","first-page":"1505665","DOI":"10.3389\/fphar.2025.1505665","article-title":"Impact of levetiracetam on direct oral anticoagulant level and outcomes among older Asian patients with atrial fibrillation","volume":"16","author":"Huang","year":"2025","journal-title":"Front Pharmacol"},{"key":"R28-20260928","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2025.2500722","article-title":"Risk of thromboembolic events in patients co-treated with factor Xa-inhibiting direct oral anticoagulants and anti-seizure medications: insights from pharmacovigilance data","volume":"1","author":"Ding","year":"2025","journal-title":"Expert Opin Drug Saf"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000003261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:00:37Z","timestamp":1790622037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000003261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003261","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"2025-12-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}